全文获取类型
收费全文 | 433318篇 |
免费 | 41189篇 |
国内免费 | 13619篇 |
专业分类
耳鼻咽喉 | 4543篇 |
儿科学 | 10148篇 |
妇产科学 | 8151篇 |
基础医学 | 31321篇 |
口腔科学 | 6407篇 |
临床医学 | 45019篇 |
内科学 | 61760篇 |
皮肤病学 | 4384篇 |
神经病学 | 12015篇 |
特种医学 | 18391篇 |
外国民族医学 | 276篇 |
外科学 | 63194篇 |
综合类 | 46584篇 |
现状与发展 | 61篇 |
一般理论 | 3篇 |
预防医学 | 25502篇 |
眼科学 | 4665篇 |
药学 | 38471篇 |
230篇 | |
中国医学 | 9489篇 |
肿瘤学 | 97512篇 |
出版年
2024年 | 1117篇 |
2023年 | 6853篇 |
2022年 | 16715篇 |
2021年 | 21303篇 |
2020年 | 15909篇 |
2019年 | 20299篇 |
2018年 | 14962篇 |
2017年 | 14588篇 |
2016年 | 17176篇 |
2015年 | 21501篇 |
2014年 | 34750篇 |
2013年 | 32345篇 |
2012年 | 32499篇 |
2011年 | 29609篇 |
2010年 | 24537篇 |
2009年 | 24321篇 |
2008年 | 23155篇 |
2007年 | 22522篇 |
2006年 | 19396篇 |
2005年 | 14135篇 |
2004年 | 9340篇 |
2003年 | 7914篇 |
2002年 | 6554篇 |
2001年 | 5739篇 |
2000年 | 4948篇 |
1999年 | 3808篇 |
1998年 | 3857篇 |
1997年 | 3409篇 |
1996年 | 2772篇 |
1995年 | 2712篇 |
1994年 | 2377篇 |
1993年 | 1824篇 |
1992年 | 1933篇 |
1991年 | 1728篇 |
1990年 | 1598篇 |
1989年 | 1511篇 |
1988年 | 1358篇 |
1987年 | 1196篇 |
1986年 | 951篇 |
1985年 | 1940篇 |
1984年 | 2028篇 |
1983年 | 1442篇 |
1982年 | 1534篇 |
1981年 | 1517篇 |
1980年 | 1304篇 |
1979年 | 1089篇 |
1978年 | 833篇 |
1977年 | 818篇 |
1976年 | 711篇 |
1975年 | 459篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
42.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
43.
44.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases. 相似文献
45.
Purnima Gogoi Geetika Kaur Nikhlesh K Singh 《World journal of gastroenterology : WJG》2022,28(46):6497-6511
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology. 相似文献
46.
47.
48.
三阴性乳腺癌(triple negative breast cancer,TNBC)是雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)及人类表皮生长因子受体(human epidermal growth factor-2,HER-2)均不表达的乳腺癌。按其功能特征可归纳为5类分子分型:以DNA修复缺陷或生长因子为途径的基底细胞样三阴性乳腺癌;以上皮-间充质转化和肿瘤干细胞为特征的间质样三阴性乳腺癌;免疫调节型三阴性乳腺癌;雄激素受体过表达的管腔/分泌型三阴性乳腺癌;HER-2富集型三阴性乳腺癌。三阴性乳腺癌恶性程度高且异型性较大,其治疗困难且预后较差,内分泌治疗及靶向治疗不敏感。目前很多学者对于三阴性乳腺癌的治疗各有研究,并有临床试验证实下述治疗有效。 相似文献
49.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
50.
目的 探讨Hsa-miR-4282在肝癌细胞系SMMC-7721中的表达及其对细胞生长的影响。方法 采用实时荧光定量PCR法检测Hsa-miR-4282在人正常肝上皮细胞系HL-7702和人肝癌细胞系MHCC97-H、SMMC-7721,以及 20例肝癌组织及其相应癌旁组织中的表达。采用瞬时转染法将Hsa-miR-4282 mimics(上调组)和Hsa-miR-4282 inhibitor(下调组)分别转染肝癌SMMC-7721细胞,上调组和下调组分别设置相应阴性对照组。转染后采用MTT法检测细胞增殖能力,平板克隆形成实验检测细胞克隆形成能力,流式细胞仪检测细胞凋亡能力。结果 Hsa-miR-4282在肝癌组织、肝癌细胞MHCC97-H及肝癌细胞SMMC-7721中的表达均低于癌旁组织及正常肝细胞HL-7702(P<0.05)。MTT实验结果显示,Hsa-miR-4282上调后肝癌SMMC-7721细胞的OD值低于其阴性对照组,而下调后OD值高于其阴性对照组 (P<0.05)。平板克隆形成实验显示,下调组的细胞克隆数高于其阴性对照组[(240±7) 个 vs (191±10) 个,P=0.005)],而上调组细胞克隆数低于基阴性对照组[(146±10) 个 vs (193±12) 个,P=0.013)]。流式细胞仪检测结果显示,Hsa-miR-4282上调组细胞凋亡率较其阴性对照组升高[(23.89±1.89)% vs(16.6±1.14)%,P=0.009)],下调组细胞凋亡率较期阴性对照组降低[(14.98±0.46)% vs (17.79±0.73)%,P=0.010]。结论 Hsa-miR-4282上调可抑制肝癌SMMC-7721细胞增殖,促进细胞凋亡,可能与肝癌的发病机制有关。 相似文献